Advance Directives Registry Offers Instant Access

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 5 No 9
Volume 5
Issue 9

NEW YORK--Choice In Dying is offering a new service that electronically stores advance directives (living wills and health care proxies). The service provides instant access to these documents with one phone call, thus avoiding the search for documents at a critical time, as, for example, when a patient becomes unconscious or unable to speak for himself.

NEW YORK--Choice In Dying is offering a new service that electronicallystores advance directives (living wills and health care proxies).The service provides instant access to these documents with onephone call, thus avoiding the search for documents at a criticaltime, as, for example, when a patient becomes unconscious or unableto speak for himself.

Choice In Dying is a national, not-for-profit organization dedicatedto fostering communication about complex end-of-life decisionsamong individuals, their loved ones, and health care professionals,and to serving the needs of dying patients and their families.The organization invented the living will in 1967 and has distributedmore than 10 million living wills since that time.

The service, DocuDIAL Advance Directives Registry, provides awallet-sized card containing instructions for family members andhealth care providers on how to retrieve the documents by fax.The service is accessible 24 hours a day, 7 days a week. Peoplecan enroll by calling 1-800-989-WILL (9455). The one-time registrationfee is $55 ($45 for members of Choice In Dying).

Applicants send photocopies of their documents, which are thenreviewed to make sure they meet the applicant's state legal requirementsand have been properly signed and witnessed. The service willnotify registrants of changes in their state laws if these occur.

Newsletter

Stay up to date on recent advances in the multidisciplinary approach to cancer.

Recent Videos
“The trial will be successful, or [we’ll] declare it a success if we see at least 3 of 24 responses overall,” stated Ravi, MD, BChir, MRCP, on the phase 2 LASER trial in RCC.
Success with the 177Lu-PSMA-617 radioligand therapy would be transformative for the clear cell renal cell carcinoma treatment landscape.
5 experts are featured in this series
4 experts in this video
2 experts are featured in this series.
4 experts in this video
4 experts in this video
4 experts in this video
2 experts are featured in this series.
Related Content